LRP6 and prostate carcinoma: In that study, the authors showed that LRP6-specific small interfering RNA (siRNA) and polyclonal antibodies raised against peptides corresponding to the extracellular domain of LRP6 could protect M2182 human prostate carcinoma cells and RAW264.7 murine macrophages from the lethal effects of FP59 or anthrax LeTx.